CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Sang Joon Shin, Jae Lyun Lee, Tae Gyun Kwon, Byoung Young Shim, Ho Seok Chung, Sang-Hee Kim, Se Hoon Park

Cancer Research and Treatment. 2023;55(2):643-651. Published online 2022 November 28 DOI: https://doi.org/10.4143/crt.2022.883

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Sang Joon Shin, Jae Lyun Lee, Tae Gyun Kwon, Byoung Young Shim, Ho Seok Chung, Sang-Hee Kim, Se Hoon Park

Cancer Research and Treatment. 2023;55(2):643-651

Link1

Link2 Link3

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

Viktor Grünwald, Merseburger

OncoTargets and Therapy. 2012;111

Link1

NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Nwamaka Umeweni, Boglarka Mikudina, Frances Sutcliffe, Andrew Stevens

The Lancet Oncology. 2015;16(4):367-368

Link1 Link2

The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy: Scottish Perspective

J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel

Value in Health. 2017;20(9):A440

Link1 Link2

Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA)

M-O. Grimm, V. Grünwald, H. Müller-Huesmann, M. Schostak, W. Schultze-Seemann, J. Bedke

European Urology Supplements. 2019;18(1):e1841

Link1 Link2

PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREA

S. Kim, S. Han, H. Kim, H.S. Suh

Value in Health. 2018;21:S39

Link1 Link2

PCN64 COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN BRAZIL

P. Serafini, S. Stefani, A. Nebel de Mello

Value in Health. 2019;22:S67

Link1 Link2

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Jie Meng, Johanna Lister, Anne-Lise Vataire, Roman Casciano, Jerome Dinet

ClinicoEconomics and Outcomes Research. 2018;Volume 10:243-250

Link1 Link2

Cost-Effectiveness in England of Cabozantinib for Patients with Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy

J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel

Value in Health. 2017;20(9):A441

Link1 Link2

Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan

Hideaki Miyake, Ken-ichi Harada, Seiichiro Ozono, Masato Fujisawa

Clinical Genitourinary Cancer. 2017;15(1):122-128

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.